Sanmenxia Central Hospital

Running trials

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Source

• Recruiting

  A Prospective, Multicenter, Randomized Controlled Trial Investigating the Impact of Fasting Duration on Postoperative Rebleeding Following Esophageal Variceal Ligation.

  NCT07774143· Source

• Not yet recruiting

  Ongericimab Injection Reducing Recurrence of Ischemic Stroke

  NCT07242599· Phase 3· Source

• Recruiting

  Phase II Trial of RC1416 Injection in Asthma

  NCT07403487· Phase 2· Source

• Recruiting

  Phase II Study of RC1416 Injection in COPD

  NCT07402551· Phase 2· Source

• Not yet recruiting

  A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis

  NCT07432854· Phase 2/3· Source

• Active, not recruiting

  A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

  NCT07230860· Phase 2· Source

• Active, not recruiting

  A Study of Zovaglutide in Subjects With Overweight or Obesity (HORIZON-1)

  NCT07230119· Phase 3· Source

• Recruiting

  JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

  NCT07284134· Phase 3· Source

• Recruiting

  ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06775860· Phase 3· Source

• Recruiting

  Observation Study on Reducing the Risk of Liver Cancer Associated With Hepatitis B (Zhiyuan) Project.

  NCT07169656· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Source

• Active, not recruiting

  A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

  NCT04344158· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Gastric and esophageal cancer2 recruiting
• Asthma1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• COPD1 recruiting
• Hepatitis B1 recruiting
• Liver and biliary tract cancer1 recruiting
• Psoriasis1 recruiting
• Stroke1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

  NCT07357831· Phase 3· Source

• Recruiting

  Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06842199· Phase 3· Source

• Completed

  Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

  NCT06631170· Phase 3· Source

• Completed

  Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

  NCT06648772· Phase 3· Source

• Completed

  To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06552520· Phase 3· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis

  NCT06700499· Phase 2· Source

• Completed

  Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06415773· Phase 3· Source

• Completed

  Efficacy and Safety of QiShen YiQi Dripping Pills in the Treatment of Diabetic Kidney Disease (Syndrome of Qi Deficiency With Blood Stasis)

  NCT06006689· Phase 2· Source

• Completed

  Evaluation of the Effect of Injectable Neucardin on Cardiac Function and Reversal Ventricular Remodeling in Patients With Chronic Systolic Heart Failure

  NCT05949801· Phase 3· Source

• Completed

  A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)

  NCT05398445· Phase 3· Source